CD274 and non-small cell lung carcinoma: A meta-analysis (12) found that overall survival (OS) and progression-free survival (PFS) advantages of ICI therapies were observed in patients with NSCLC with low or high programmed cell death 1 ligand 1 (PD‐L1) expression levels but not in intermediate PD‐L1 TPS patients.